Tislelizumab for the treatment of unresectable or metastatic esophageal squamous cell carcinoma.
gastroesophageal junction cancer
Posted inOncology, Regulatory
Opdivo and Keytruda: First-line Immunotherapy for Gastric Cancer and Esophageal Cancer
Nivolumab or pembrolizumab should be added to standard chemotherapy to prolong the life of patients with gastric, esophageal, and gastroesophageal junction cancers.
Posted inClinical Trials, Oncology
Bemarituzumab: Breakthrough in Gastric Cancer Treatment
A new and effective targeted therapy, being developed by Five Prime Therapeutics and Amgen, for a deadly cancer disease in the past decade.